Fiche du document
- doi: 10.1038/s41416-021-01474-y
- issn: 0007-0920
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1038/s41416-021-01474-y
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/34426663
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1532-1827
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_9EA83BC830BF6
info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/
Sujets proches
State trials Hepatocellular carcinoma Therapeutic immunology GI tract Gastrointestinal tract Tract, Gastrointestinal Gastro-intestinal system Tract, GI Carcinoma Cancers Malignancy (Cancer) Malignant tumorsCiter ce document
T. Koessler et al., « Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group. », Serveur académique Lausannois, ID : 10.1038/s41416-021-01474-y
Métriques
Partage / Export
Résumé
Last year the field of immunotherapy was finally introduced to GI oncology, with several changes in clinical practice such as advanced hepatocellular carcinoma or metastatic colorectal MSI-H. At the virtual ASCO-GI symposium 2021, several large trial results have been reported, some leading to a change of practice. Furthermore, during ASCO-GI 2021, results from early phase trials have been presented, some with potential important implications for future treatments. We provide here an overview of these important results and their integration into routine clinical practice.